Tofacitinib Inhibits S100A7 Expression in Human Keratinocytes

DOI HANDLE Web Site Open Access
  • Furue Kazuhisa
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
  • Hashimoto-Hachiya Akiko
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
  • Satake Mao
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
  • Kuretake Keisuke
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
  • Sakai Eriko
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
  • Shiomichi Yasuko
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
  • Imamura Sakurako
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
  • Sasaki Natsuki
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
  • Yano Atsuko
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
  • Nakamura Mayuka
    九州大学大学院医学研究院皮膚科学分野
  • Nagai Kiko
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
  • Fujii Haruka
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University
  • Hurue Masutaka
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University Division of Skin Surface Sensing, Department of Dermatology, Graduate School of Medical Sciences, Kyushu University Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital
  • Tsuji Gaku
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University

Bibliographic Information

Other Title
  • Tofacitinibはヒト表皮細胞のS100A7発現を抑制する

Search this article

Abstract

Atopic dermatitis (AD) is associated with multifaceted immune-system and epithelial abnormalities. S100A7 is overexpressed in keratinocytes in AD and its elevation is involved in the exacerbation of atopic barrier dysfunction. Tofacitinib is a Janus kinase inhibitor that is anticipated to become a new treatment strategy for AD. However, it has remained unclear whether tofacitinib inhibits S100A7 expression in keratinocytes. In this study, we demonstrated that tofacitinib did indeed inhibit the baseline and 6-formylindolo[3,2-b]carbazole-induced expression of S100A7. This inhibitory action can potentially contribute to the efficacy of tofacitinib for AD.

Journal

  • 福岡醫學雜誌

    福岡醫學雜誌 109 (4), 91-95, 2018-12-25

    Fukuoka Medical Association

Keywords

Details 詳細情報について

Report a problem

Back to top